Eli Lilly & Co
Taltz and Zepbound
adults with psoriasis and obesity or overweight
Resolved
68days ago
Phase 3 readout · Apr 30, 2026
What's at stake
Phase 3 trial results for Taltz and Zepbound in adults with psoriasis and obesity or overweight are due Apr 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“positive Phase 3 results from Taltz and Zepbound used together for adults with psoriasis and obesity or overweight,”